Alzheimer’s

Therapeutic antibodies
#Alzheimer's #Antibodies #Cancer #Covid-19 #Engineered antibodies #Immunology #Janssen #Monoclonal antibodies #Rare disease #Therapeutic Antibodies

Podcast: Where is the innovation in the therapeutic antibody market?

This is the latest episode of the free DDW narrated podcast, titled “Where is the innovation in the therapeutic antibody market?”, which covers two articles written for DDW Volume 24 – Issue 3, Summer 2023. They are called: “Finding the North Star of therapeutic antibodies” and “Which diseases… Read More

#News

Drugs targeting amyloid Plaque
#Alzheimer's #Drug safety #Eisai #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE)

Researchers call for extra safety monitoring of lecanemab

Researchers from the UK’s Drug Safety Research Unit are calling for the robust monitoring of the safety of lecanemab, a new drug to treat Alzheimer’s disease (AD).  In a review article, published in the British Journal for Clinical Pharmacology, the… Read More

#News #Regulatory #Trending News

Map of Iceland
#Alzheimer's #Arctic Therapeutics #Dementia #Dermatology #Financing #Neuroscience

Scale-up explores anti-amyloid treatments for dementia

Icelandic drug discovery and development company Arctic Therapeutics (ATx) has announced the successful closing of a €26.5 million oversubscribed Series A financing from a syndicate of international investors.  The syndicate includes the EIC Fund, Iceland’s largest privately-held investment firm Kaldbakur, Investcorp-backed Sanos Group, Swiss-based Cerebrum DAO, The… Read More

#Business & Investment #News

Tau proteins
#Alzheimer's #Fast Track designation #FDA #Johnson & Johnson #Monoclonal antibodies #Neuroscience

Tau-directed mAb receives US FDA fast track designation

The US Food and Drug Administration (FDA) has granted Fast Track designation to posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb).  The therapy from Johnson & Johnson is being investigated to treat patients with early Alzheimer’s disease (AD) in the Phase IIb AuTonomy study.   It has… Read More

#News #Regulatory

#Alzheimer's #Collaboration #GSK #Muna Therapeutics #Neuroscience #Transcriptomics

GSK and Muna ally on novel treatments for Alzheimer’s disease

GSK and biotechnology company Muna Therapeutics have entered a research alliance to identify and validate novel drug targets for the treatment of Alzheimer’s disease.   The companies will explore insights from Muna’s MiND-MAP platform, which applies spatial transcriptomics to brain samples from Alzheimer’s disease patients, cognitively resilient individuals,… Read More

#Business & Investment #News

#AI / data analytics / healthtech / informatics #Alzheimer's #Automation #Biomarkers #Data automation #Data management #Digital biomarkers #Digitalisation #Drug development #Drug discovery #Genetics / genomics #Mass spectrometry / NMR #Neurodegenerative disorders #Neuroscience

New podcast: The far-reaching impact of drug discovery technology

This is the latest episode of the free DDW narrated podcast, titled “The far-reaching impact of drug discovery technology”, which covers three articles written for DDW Volume 24 – Issue 2, Spring 2023 of DDW. They are called: “Accelerating time to market through digitalisation”, “… Read More

#News

#Alzheimer's #Neuroscience #Non-animal model (NAM) #Preclinical investigations

‘Alzheimer’s in dish’ 3D model shows promise for drug discovery

A decade ago, researchers introduced a new model for studying Alzheimer’s disease (AD). Known as ‘Alzheimer’s in a dish’, the model uses cultures of mature brain cells suspended in a gel to recapitulate what takes place in the human brain over 10 to 13 years in just six weeks. Read More

#News

Tau proteins
#Alzheimer's #Neuroscience #Phase II trial #Tau protein #UCB

Encouraging results for anti-tau antibody presented at CTAD 2024

UCB has reported encouraging Phase IIa data from the TOGETHER (AH0003) study, investigating bepranemab, an anti-tau antibody targeting the mid-region of the tau protein in people living with prodromal to mild Alzheimer’s disease. The results were presented during a late-breaking symposium at the 2024 Clinical Trials… Read More

#News

CT scans of the brain
#Alzheimer's #Clinical trial #Dementia #UK

Accelerator to boost dementia clinical trial participation in UK 

A new initiative hopes to increase the number of people participating in dementia clinical trials in the UK, aiming to identify tens of thousands of potential trial participants.  The new ‘Dementia Trials Accelerator’ initiative hopes to address pharma-identified roadblocks to the delivery of commercial clinical trials in… Read More

#News

Dementia
#Alzheimer's #Drug development #Eli Lilly #Monoclonal antibodies #National Institute for Health and Care Excellence (NICE) #Regulatory

UK’s NICE rejects second disease-modifying therapy for Alzheimer’s 

UK regulator the National Institute for Health and Care Excellence (NICE) has ruled against the use of a second monoclonal antibody for Alzheimer’s disease, just two months after rejecting Eisai’s lecanemab (Leqembi).  NICE concluded that Eli Lilly’s donanemab (Kisunla) only provides a “small benefit”… Read More

#News

Tau proteins
#Alzheimer's #Neurodegenerative disorders #Tau protein #University of Cambridge

New therapy targets and destroys tau tangles in Alzheimer’s

Scientists have developed two new potential therapies that selectively remove aggregated tau proteins, which are associated with Alzheimer’s disease, and improve symptoms of neurodegeneration in mice. They say this promising approach could also be applied in future to other brain disorders driven by protein aggregation inside… Read More

#News #Trending News

Natural killer cells
#Alzheimer's #Cell therapy #Natural killer cells #Neurodegenerative disorders #NKGen #Phase I trial

Positive early data for Alzheimer’s natural killer cell therapy

NKGen Biotech has announced promising early interim data from the Phase I cohort trial of troculeucel, its cryopreserved autologous enhanced natural killer (NK) cell therapy for moderate Alzheimer’s disease (AD). An early independent review of the Phase I data shows that after three months treatment with… Read More

#Editor's Choice #News

Lecanemab
#Alzheimer's #Eisai #National Institute for Health and Care Excellence (NICE) #Neurodegenerative disorders #UK

UK regulator rules benefits of lecanemab do not justify the cost

The benefits of Alzheimer’s drug lecanemab (Leqembi) are too small to justify the cost of providing the treatment to NHS patients, the UK regulator has ruled. This was the decision by the National Institute for Health and Care Excellence (NICE) in draft guidance on the drug. Read More

#News #Regulatory #Trending News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights vodcast: 7 August 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   GLP-1 receptor agonists have dominated… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

New DDW Highlights podcast: 5 August 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on… Read More

#News

#Alzheimer's #Cardiovascular disease #GLP-1 #Liver disease #Nicotine addiction #Obesity #Weight loss

This week in drug discovery (29 July – 2 August) 

News round-up for 29 July – 2 August by DDW Senior Digital Content Editor Diana Spencer. GLP-1 receptor agonists have dominated the headlines this week, with data revealed on new potential beneficial effects of treatment with semaglutide and dual receptor agonists like pemvidutide. The top stories:… Read More

#News